Resveratrol prevents gallstones in mice fed on a high fat diet via regulating PPAR-γ and SR-BI
Resveratrol demonstrates significant potential as a therapeutic agent for the prevention and treatment of cholesterol gallstone disease (CGD) by modulating hepatic cholesterol metabolism, reducing bile cholesterol saturation, and alleviating hepatic inflammation. Further studies are warranted to explore its clinical applicability in humans.
Authors
- Tiantian Zhu (ORCID: https://orcid.org/0000-0001-9017-6680)
- Rui Li (ORCID: https://orcid.org/0000-0002-6474-9702)
- Baojun Xie (ORCID: https://orcid.org/0000-0001-9581-5322)
- Xiaolong Wu (ORCID: https://orcid.org/0000-0001-9059-0005)
- Haiqing Dong (ORCID: https://orcid.org/0000-0001-6428-5904)
- Shiyi Sun (ORCID: https://orcid.org/0000-0002-0229-6066)
- Yuxuan Li (ORCID: https://orcid.org/0000-0001-9787-2160)
- Jian Zhang (ORCID: https://orcid.org/0000-0001-5552-0132)
- Yinghai Xie
- Menglu Zhao (ORCID: https://orcid.org/0009-0007-7992-6429)
- Chengchen Xu (ORCID: https://orcid.org/0000-0002-6436-9056)
- Sijia Jiang
Institutions
- Second Military Medical University (CN)
- Anhui University of Science and Technology (CN)
- Academic Degrees & Graduate Education (CN)
- Eastern Hepatobiliary Surgery Hospital (CN)
- Jiangsu Province Hospital (CN)
- Huainan Mining Industry Group (China) (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-03-17
- DOI
- https://doi.org/10.3389/fphar.2025.1543865
- Primary Topic
- Peroxisome Proliferator-Activated Receptors
- Type
- article
- Field-Weighted Citation Impact
- 0.00